{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T23:27:19Z","timestamp":1780702039352,"version":"3.54.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T00:00:00Z","timestamp":1494288000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s11926-017-0664-6","type":"journal-article","created":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T06:34:18Z","timestamp":1494311658000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Pneumocystis Pneumonia and the Rheumatologist: Which Patients Are At Risk and How Can PCP Be Prevented?"],"prefix":"10.1007","volume":"19","author":[{"given":"Rachel M.","family":"Wolfe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"James E.","family":"Peacock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,9]]},"reference":[{"key":"664_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005590.pub3","author":"A Stern","year":"2014","unstructured":"Stern A, Green H, Paul M, et al. Prophylaxis for pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2014; doi: 10.1002\/14651858.CD005590.pub3 .","journal-title":"Cochrane Database Syst Rev"},{"key":"664_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1471-2334-4-42","volume":"4","author":"E Sowden","year":"2004","unstructured":"Sowden E, Carmichael AJ. Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention. BMC Infect Dis. 2004;4:42. doi: 10.1186\/1471-2334-4-42 .","journal-title":"BMC Infect Dis"},{"key":"664_CR3","unstructured":"Centers for Disease Control and Prevention: Pneumoycstis pneumonia. https:\/\/www.cdc.gov\/fungal\/diseases\/pneumocystis-pneumonia (2014). Accessed 17 Feb 2017."},{"issue":"2","key":"664_CR4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1128\/CMR.00013-12","volume":"25","author":"A Morris","year":"2012","unstructured":"Morris A, Norris K. Colonization by pneumocystis jirovecii and its role in disease. Clin Microbiol Rev. 2012;25(2):297\u2013317.","journal-title":"Clin Microbiol Rev"},{"issue":"9","key":"664_CR5","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.4065\/82.9.1052","volume":"82","author":"H Green","year":"2007","unstructured":"\u2022\u2022 Green H, Paul M, Vidal L, et al. Prophylaxis of pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007;82(9):1052\u20139. This study reviews data for PCP prophylaxis with special attention to CTD.","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"664_CR6","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1177\/1060028016650107","volume":"50","author":"LJ Avino","year":"2016","unstructured":"Avino LJ, Naylor SM, Roecker AM. Pneumocystis jirovecii pneumonia in the non-HIV-infected population. Ann Pharmacol. 2016;50(8):673\u20139.","journal-title":"Ann Pharmacol"},{"issue":"4","key":"664_CR7","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/1529-0131(199904)42:4<780::AID-ANR23>3.0.CO;2-M","volume":"42","author":"MM Ward","year":"1999","unstructured":"Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum. 1999;42(4):780\u20139.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"664_CR8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/01.rhu.0000221794.24431.36","volume":"12","author":"J Li","year":"2006","unstructured":"Li J, Huang XM, Fang WG, et al. Pneumocystis carinii pneumonia in patients with connective tissue disease. J Clin Rheumatol. 2006;12(3):114\u20137.","journal-title":"J Clin Rheumatol"},{"issue":"4","key":"664_CR9","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3899\/jrheum.090843","volume":"37","author":"D Cettomai","year":"2010","unstructured":"Cettomai D, Gelber AC, Christopher-Stine L. A survey of rheumatologists\u2019 practice for prescribing pneumocystis prophylaxis. J Rheumatol. 2010;37(4):792\u20139.","journal-title":"J Rheumatol"},{"key":"664_CR10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/RHU.0b013e31817a7e30","volume":"14","author":"D Gupta","year":"2008","unstructured":"Gupta D, Zachariah A, Roppelt H, et al. Prophylactic antibiotic usage for pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of US rheumatologist and the review of literature. J Clin Rheumatol. 2008;14:267\u201372.","journal-title":"J Clin Rheumatol"},{"key":"664_CR11","doi-asserted-by":"publisher","first-page":"686","DOI":"10.3899\/jrheum.091426","volume":"37","author":"LK Stamp","year":"2010","unstructured":"Stamp LK, Hurst M. Is there a role for consensus guidelines for P. jiroveci pneumonia prophylaxis in immunosuppressed patients with rheumatic disease? J Rheumatol. 2010;37:686\u20138.","journal-title":"J Rheumatol"},{"key":"664_CR12","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s10067-006-0441-9","volume":"26","author":"ME Falagas","year":"2007","unstructured":"\u2022\u2022 Falagas ME, Manta KG, Betsi GI, et al. Infection-related morbidity and mortality in patients with connective tissue diseases: a systemic review. Clin Rheumatol. 2007;26:663\u201370. This study details infectious complications, including PCP, for the CTDs with large numbers of patients included.","journal-title":"Clin Rheumatol"},{"issue":"2","key":"664_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/art.21083","volume":"53","author":"I Marie","year":"2005","unstructured":"Marie I, Hachulla E, Cherin P, et al. Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum. 2005;53(2):155\u201365.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"664_CR14","first-page":"1186","volume":"23","author":"A Kadoya","year":"1996","unstructured":"Kadoya A, Okada J, Iikuni Y, et al. Risk factors for pneumocystis carinii pneumonia in patients with polymyositis\/dermatomyositis or systemic lupus erythematosus [abstract]. J Rheumatol. 1996;23(7):1186\u20138.","journal-title":"J Rheumatol"},{"key":"664_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.09.009","author":"S Tadros","year":"2016","unstructured":"\u2022 Tadros S, Teichtahl AJ, Ciciriello S, et al. Pneumocystis jirovecii in systemic autoimmune rheumatic disease: a case-control study. Semin Arthritis Rheum. 2016; doi: 10.1016\/j.semarthrit.2016.09.009 . Case series examining risk factors for PCP while controlling for the specific rheumatic disease.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"664_CR16","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1378\/chest.118.3.712","volume":"118","author":"NG Mansharamani","year":"2000","unstructured":"Mansharamani NG, Balachandran D, et al. Peripheral blood CD4 + T-lymphocyte counts during pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest. 2000;118(3):712\u201320.","journal-title":"Chest"},{"issue":"9","key":"664_CR17","doi-asserted-by":"publisher","first-page":"e0139144","DOI":"10.1371\/journal.pone.0139144","volume":"10","author":"M Chen","year":"2015","unstructured":"Chen M, Tian X, Qin F, et al. Pneumocystis pneumonia in patients with autoimmune disease: a retrospective study focused on clinical characteristics and prognostic factors related to death. PLoS One. 2015;10(9):e0139144. doi: 10.1371\/journal.pone.0139144 .","journal-title":"PLoS One"},{"key":"664_CR18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.semarthrit.2015.01.007","volume":"45","author":"AJ Teichtahl","year":"2015","unstructured":"Teichtahl AJ, Morrisroe K, Ciciriello S, et al. Penumocystis jirovecci pneumonia in connective tissue diseases: comparison with other immunocompromised patients. Semin Arthritis Rheum. 2015;45:86\u201390.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"664_CR19","first-page":"615","volume":"11","author":"B Jarrousse","year":"1993","unstructured":"Jarrousse B, Guillevin L, Bindi P, et al. Increased risk of pneumocystis carinii pneumonia in patients with wegener\u2019s granulomatosis [abstract]. Clin Exp Rheumatol. 1993;11(6):615\u201321.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"664_CR20","first-page":"246","volume":"21","author":"B Godeau","year":"1994","unstructured":"Godeau B, Coutant-Perronne V, Huong DLT, et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol. 1994;21(2):246\u201351.","journal-title":"J Rheumatol"},{"key":"664_CR21","first-page":"795","volume":"151","author":"FP Ognibene","year":"1995","unstructured":"Ognibene FP, Shelhamer JH, Hoffman GS, et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with wegener\u2019s granulomatosis. Am J Respir Crit Care Med. 1995;151:795\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"664_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3109\/PL00021707","volume":"15","author":"J Ogawa","year":"2005","unstructured":"Ogawa J, Harigai M, Nagasaka K, et al. Prediction of and prophylaxis against pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy. Mod Rheumatol. 2005;15:91\u20136.","journal-title":"Mod Rheumatol"},{"key":"664_CR23","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s00296-014-3073-4","volume":"34","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Zheng Y. Pneumocystis jirovecii pneumonia in mycophenolate mofetil-treated patients with connective tissue disease: analysis of 17 cases. Rheumatol Int. 2014;34:1765\u201371.","journal-title":"Rheumatol Int"},{"key":"664_CR24","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1136\/ard.54.12.991","volume":"54","author":"B Godeau","year":"1995","unstructured":"Godeau B, Mainardi JL, Roudot-Thoraval F, et al. Factors associated with pneumocystis carinii pneumonia in wegener\u2019s granulmatosis. Ann Rheum Dis. 1995;54:991\u20134.","journal-title":"Ann Rheum Dis"},{"key":"664_CR25","first-page":"1191","volume":"19","author":"AJ Porges","year":"1992","unstructured":"Porges AJ, Beattie SL, et al. Patients with systemic lupus erythematosus at risk for pneumocystis carinii pneumonia. J Rheumatol. 1992;19:1191\u20134.","journal-title":"J Rheumatol"},{"key":"664_CR26","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/RHU.0000000000000215","volume":"21","author":"LC Chew","year":"2015","unstructured":"Chew LC, Maceda-Galang LM, Tan YK, et al. Pneumocystis jirovecii pneumonia in patients with autoimmune disease on high-dose glucocorticoid. J Clin Rheumatol. 2015;21:72\u20135.","journal-title":"J Clin Rheumatol"},{"issue":"11","key":"664_CR27","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.11150\/kansenshogakuzasshi1970.73.1123","volume":"73","author":"J Okada","year":"1999","unstructured":"Okada J, Kadoya A, Rana M, et al. Efficacy of sulfamethoxazole-trimthoprim administration in the prevention of pneumocystis carinii pneumonia in patients with connective tissue disease. Kansenshogaku Zasshi. 1999;73(11):1123\u20139.","journal-title":"Kansenshogaku Zasshi"},{"key":"664_CR28","unstructured":"Mecoli CA, Saylor D, Gelber AC, et al. Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience [abstract]. Clin Exp Rheumatol 2017; Accessed 2\/17\/17."},{"issue":"1","key":"664_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4065\/71.1.5","volume":"71","author":"SH Yale","year":"1996","unstructured":"Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996;71(1):5\u201313.","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"664_CR30","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/acr.20435","volume":"63","author":"TA Kermani","year":"2011","unstructured":"Kermani TA, Ytterberg SR, Warrington KJ. Pneumocystis jiroveci pneumonia in giant cell arteritis: a case series. Arthritis Care Res. 2011;63(5):761\u20135.","journal-title":"Arthritis Care Res"},{"issue":"12","key":"664_CR31","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1002\/art.1780401213","volume":"40","author":"L Guillevin","year":"1997","unstructured":"Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized wegener\u2019s granulomatosis. Arthritis Rheum. 1997;40(12):2187\u201398.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"664_CR32","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/acr.21857","volume":"65","author":"MK Demoruelle","year":"2013","unstructured":"Demoruelle MK, Kahr A, Verilhac K, et al. Recent-onset systemic lupus erythematosus complicated by acute respiratory failure. Arthritis Care Res. 2013;65(2):314\u201323.","journal-title":"Arthritis Care Res"},{"issue":"12","key":"664_CR33","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1093\/cid\/ciu185","volume":"58","author":"IS Kourbeti","year":"2014","unstructured":"Kourbeti IS, Ziakas PD, Mylonakis E. Biologic therapies in rheumatoid arthritis and risk of opportunistic infections: a meta-analysis. Clin Infect Dis. 2014;58(12):1649\u201357.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"664_CR34","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.semarthrit.2010.08.003","volume":"41","author":"I Marie","year":"2011","unstructured":"Marie I, Menard JF, Hachulla E, et al. Infectious complications in polymyositis and dermatomyositis: a series of 279 patients. Semin Arthritis Rheum. 2011;41(1):48\u201360.","journal-title":"Semin Arthritis Rheum"},{"key":"664_CR35","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/j.1440-1843.2012.02158.x","volume":"17","author":"E Hardak","year":"2012","unstructured":"Hardak E, Neuberger A, Yigla M, et al. Outcome of pneumocystis jirovecii pneumonia diagnosed by polymerase chain reaction in patients without human immunodeficiency virus infection. Respirology. 2012;17:681\u20136.","journal-title":"Respirology"},{"key":"664_CR36","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.semarthrit.2011.05.004","volume":"41","author":"P Vananuvat","year":"2011","unstructured":"Vananuvat P, Suwannalai P, Sungkanuparph S, et al. Primary prophylaxis for pneumocystis jirovecii pneumonia in patients with connective tissue diseases. Semin Arthritis Rheum. 2011;41:497\u2013502.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"664_CR37","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1213277","volume":"369","author":"U Specks","year":"2013","unstructured":"Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013;369(5):417\u201327.","journal-title":"N Engl J Med"},{"issue":"19","key":"664_CR38","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771\u201380.","journal-title":"N Engl J Med"},{"key":"664_CR39","unstructured":"UpToDate: Drug information. https:\/\/www.uptodate.com (2017). Accessed 7 Mar 2017."},{"key":"664_CR40","doi-asserted-by":"publisher","first-page":"730","DOI":"10.4065\/74.7.730","volume":"74","author":"JD Smilack","year":"1999","unstructured":"Smilack JD. Trimethoprim-sulfamethoxazole. Mayo Clin Proc. 1999;74:730\u20134.","journal-title":"Mayo Clin Proc"},{"key":"664_CR41","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/2047-783X-14-S4-265","volume":"14","author":"K Zycinska","year":"2009","unstructured":"Zycinska K, Wardyn KA, Zielonka TM, et al. Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement. Eur J Med Res. 2009;14:265\u20137.","journal-title":"Eur J Med Res"},{"issue":"1","key":"664_CR42","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1056\/NEJM199607043350103","volume":"355","author":"CA Stegeman","year":"1996","unstructured":"Stegeman CA, Tervaert JW. Trimethoprime-suflamethoxazole(co-trimoxazole) for the prevention of relapses of Wegener\u2019s granulomatosis. Dutch co-trimoxazole wegener study group. N Engl J Med. 1996;355(1):16\u201320.","journal-title":"N Engl J Med"},{"key":"664_CR43","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1445-5994.2007.01382.x","volume":"37","author":"K Meuli","year":"2007","unstructured":"Meuli K, Chapman P, O\u2019Donnell J, et al. Audit of pneumocystis pneumonia in patients seen by christchurch hospital rheumatology service over a 5-year period. Intern Med J. 2007;37:687\u201392.","journal-title":"Intern Med J"},{"issue":"7","key":"664_CR44","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.3899\/jrheum.090153","volume":"37","author":"J Bourre-Tessier","year":"2010","unstructured":"Bourre-Tessier J, Haraoui B. Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review. J Rheumatol. 2010;37(7):1416\u201321.","journal-title":"J Rheumatol"},{"issue":"3","key":"664_CR45","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/eci.12410","volume":"45","author":"A Kronbichler","year":"2015","unstructured":"Kronbichler A, Jayne DRW, Mayer G. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Investig. 2015;45(3):346\u201368.","journal-title":"Eur J Clin Investig"},{"key":"664_CR46","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones RB, Tervaert JWC, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363:211\u201320.","journal-title":"N Engl J Med"},{"issue":"3","key":"664_CR47","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221\u201332.","journal-title":"N Engl J Med"},{"key":"664_CR48","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","volume":"75","author":"M Yates","year":"2016","unstructured":"\u2022 Yates M, Watts RA, Bajema IM, et al. EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75:1583\u201394. EULAR recommendations for treatment of ANCA Vasculitis which includes recommendations on PCP prophylaxis.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"664_CR49","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s10067-010-1408-4","volume":"29","author":"FH Souza de","year":"2010","unstructured":"de Souza FH, Radu Halpern AS, et al. Wegener\u2019s granulomatosis: experience from a Brazilian tertiary center. Clin Rheumatol. 2010;29(8):855\u201360.","journal-title":"Clin Rheumatol"},{"issue":"8","key":"664_CR50","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1002\/1529-0131(200008)43:8<1841::AID-ANR21>3.0.CO;2-Q","volume":"43","author":"JB Chung","year":"2000","unstructured":"Chung JB, Armstrong K, Schwartz S, et al. Cost-effectiveness of prophylaxis against pneumocystis carinii pneumonia in patients with wegener\u2019s granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum. 2000;43(8):1841\u20138.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"664_CR51","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1002\/acr.20279","volume":"62","author":"B Hugle","year":"2012","unstructured":"Hugle B, Solomon M, Harvey E, et al. Pneumocystis jiroveci pneumonia following rituximab treatment in wegener\u2019s granulomatosis. Arthritis Care Res. 2012;62(11):1661\u20134.","journal-title":"Arthritis Care Res"},{"issue":"8","key":"664_CR52","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1086\/339548","volume":"34","author":"KA Sepkowitz","year":"2002","unstructured":"Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis. 2002;34(8):1098\u2013107.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"664_CR53","first-page":"265","volume":"19","author":"M Petri","year":"1992","unstructured":"Petri M, Allbritton J. Antibiotic allergy in systemic lupus erythematosus: a case-control study. J Rheumatol. 1992;19(2):265\u20139.","journal-title":"J Rheumatol"},{"key":"664_CR54","first-page":"480","volume":"30","author":"J Pope","year":"2003","unstructured":"Pope J, Jerome D, Fenlon D, et al. Frequency of adverse drug reactions in patients with systemic lupus erythematosus. J Rheumatol. 2003;30:480\u20134.","journal-title":"J Rheumatol"},{"key":"664_CR55","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3109\/s10165-012-0625-x","volume":"23","author":"R Maezawa","year":"2013","unstructured":"Maezawa R, Kurasawa K, Arai S, et al. Positivity for anti-RNP antibody is a risk factor for adverse effects caused by trimethoprim\u2013sulfamethoxazole, a prophylactic agent for P. jiroveci pneumonia, in patients with connective tissue diseases. Mod Rheumatol. 2013;23:62\u201370.","journal-title":"Mod Rheumatol"},{"issue":"11","key":"664_CR56","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1136\/annrheumdis-2013-203407","volume":"73","author":"JW Baddley","year":"2014","unstructured":"Baddley JW, Winthrop KL, Chen L, et al. Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the safety assessment of biologic therapy (SABER) study. Ann Rheum Dis. 2014;73(11):1942\u20138.","journal-title":"Ann Rheum Dis"},{"key":"664_CR57","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s11926-014-0445-4","volume":"16","author":"JA Grubbs","year":"2014","unstructured":"\u2022 Grubbs JA, Baddley JW. Pneumocystis jirovecii pneumonia in patients receiving tumor-necrosis-factor-inhibitor therapy: implications for chemoprophylaxis. Curr Rheumatol Rep. 2014;16:445. Large meta-analysis of PCP in rheumatoid arthritis with a specific focus on biologic therapy.","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"664_CR58","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1756-185X.2012.01728.x","volume":"15","author":"C Foocharoen","year":"2012","unstructured":"Foocharoen C, Siriphannon Y, Mahakkanukrauh A, et al. Incidence rate and causes of infection in Thai systemic sclerosis patients. Int J Rheum Dis. 2012;15(3):277\u201383.","journal-title":"Int J Rheum Dis"},{"key":"664_CR59","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655\u201366.","journal-title":"N Engl J Med"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-017-0664-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-017-0664-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-017-0664-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:40:59Z","timestamp":1719189659000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-017-0664-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,9]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["664"],"URL":"https:\/\/doi.org\/10.1007\/s11926-017-0664-6","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,9]]},"assertion":[{"value":"9 May 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Rachel M. Wolfe and James E. Peacock, Jr. declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"35"}}